NCT05831787Completed
COVID19 OutcomeS in Myeloma and the Impact of VaCcines
Monitoring SARS-CoV-2 Vaccines and COVID-19 Related Outcomes in Individuals With Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
The COVID-19 pandemic has had an outsized impact on individuals with underlying social and medical vulnerability, leading to increased rates of severe disease, hospitalization, and death in these groups. Participants with underlying immune compromise, such as those with multiple myeloma, represent one such group. The advent of vaccines against SARS-CoV-2 has significantly limited morbidity and mortality across all groups, but the effectiveness of vaccination in individuals who are less likely to mount sufficient antibody response is uncertain. For this reason, booster vaccines have been recommended for those with underlying immune compromise. However, several key gaps remain in our understanding of how to best protect these individuals. There is a dearth of real-world evidence about the effectiveness of vaccination and boosters in patients who are immunocompromised, and very little information specifically about the recently approved mRNA boosters. Additionally, rates of vaccination and booster uptake in the United States remain low. A rapid, decentralized method of ascertaining information related to booster vaccine response and adverse events related to vaccines and COVID-19 infection is critical not only to answer questions about the booster vaccines, but to develop an infrastructure for answering similar questions about future vaccines or other diseases.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 201 (actual)
- First submitted
- 20 Apr 2023
- Start date
- 23 Jan 2024
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- ASH Research Collaborative
- Diseases
- Multiple myeloma, Childhood cancers
- NCT number
- NCT05831787
What you commit to
- Study type: Observational
- Participants enrolled: 201
- From 23 Jan 2024 to the primary completion date, 31 Dec 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cognitive impairment precluding ability to provide informed consent
Other
- Non-English speaking
- Lack of internet access
Who the study is looking for
- Diagnosis of multiple myeloma per the International Myeloma Working Group and currently receiving active treatment for any phase of the disease, including initial therapy, maintenance, or relapsed disease.
- Access to the internet
- An active patient portal (or willingness to activate)
- Willing to electronically sign the study-specific informed consent and authorization form
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UNC- Chapel Hill Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
Related publications
- Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma.Blood Adv · 2026 · PMID 41734388
This page is information, not medical advice. Discuss any trial with your doctor.